Drugs / AdGMCAIX-transduced autologous dendritic cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01826877 | Jan 2013 → Jul 2018 | clear cell renal carcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdGMCAIX-transduced autologous dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01826877 ↗ |
| Known as | Ad-GMCAIX | “These preliminary data support further study of Ad-GMCAIX, particularly with combination therapies that may enhance clinical activity.” PMID 32925563 ↗ Nov 2020 |
| Known as | AdGMCA9 | “A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9...” PMID 32925563 ↗ Nov 2020 |
| Modality | Cell therapy | “We developed a fusion-gene construct, granulocyte-macrophage (GM) colony-stimulating factor+CAIX, delivered by an adenoviral vector (Ad) into autologous dendritic cells (DCs)...” PMID 32925563 ↗ Nov 2020 |
| Target | CAIX | “Expression of carbonic-anhydrase IX (CAIX) in clear cell renal cell carcinoma (RCC) makes it an attractive vaccine target.” PMID 32925563 ↗ Nov 2020 |